Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 247

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Antibiotics in late clinical development

Open access
Fernandes, Prabhavathi, Martens, Evan·2017·Biochemical Pharmacology

Abstract

Most pharmaceutical companies have stopped or have severely limited investments to discover and develop new antibiotics to treat the increasing prevalence of infections caused by multi-drug resistant bacteria, because the return on investment has been mostly negative for antibiotics that received marketing approved in the last few decades. In contrast, a few small companies have taken on this challenge and are developing new antibiotics. This review describes those antibiotics in late-stage clinical development. Most of them belong to existing antibiotic classes and a few with a narrow spectrum of activity are novel compounds directed against novel targets. The reasons for some of the past failures to find new molecules and a path forward to help attract investments to fund discovery of new antibiotics are described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2016.09.025

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Fernandes, 2006, Antibacterial discovery and development—the failure of success?, Nat. Biotechnol., 24, 1497, 10.1038/nbt1206-1497 · DOI · Paper page
  2. O’Neill, 2016, Tackling drug-resistant infections globally: final report and recommendations, Rev. Antimicrob. Resist.
  3. Corey, 2014, Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections, Antimicrob. Agents Chemother., 58, 6518, 10.1128/AAC.03360-14 · DOI
  4. Ling, 2015, A new antibiotic kills pathogens without detectable resistance, Nature, 517, 455, 10.1038/nature14098 · DOI · Paper page
  5. Taber, 2005, Total synthesis of the tetracyclines, Org. Chem. Highlights
  6. Seiple, 2016, A platform for the discovery of new macrolide antibiotics, Nature, 533, 338, 10.1038/nature17967 · DOI · Paper page
  7. Das, 2009, Biosynthesis of aromatic polyketides in bacteria, Acc. Chem. Res., 42, 631, 10.1021/ar8002249 · doi:10.1021/ar8002249
  8. Cane, 2016, Nature as organic chemist, J. Antibiot., 69, 473, 10.1038/ja.2016.55 · doi:10.1038/ja.2016.55
  9. Blum, 1994, Temafloxacin syndrome: review of 95 cases, Clin. Infect. Dis., 18, 946, 10.1093/clinids/18.6.946 · DOI
  10. Shaw, 2010, Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity, Toxicol. Sci., 118, 7, 10.1093/toxsci/kfq168 · DOI · Paper page
  11. Ross, 2007, The FDA and the case of Ketek, N. Eng. J. Med., 356, 1601, 10.1056/NEJMp078032 · DOI
  12. Association for Professionals in Infection Control and Epidemiology (APIC), Antimicrobial Stewardship, <http://www.apic.org/Professional-Practice/Practice-Resources/Antimicrobial-Stewardship> (accessed 9.15.2016). · doi:10.1079/9781780644394.0015
  13. Currie, 2014, Antibiotic treatment failure in four common infections in UK primary care 1991–2012: longitudinal analysis, Br. Med. J., 349, g5493, 10.1136/bmj.g5493 · DOI
  14. Zhanel, 2013, Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination, Drugs, 73, 159, 10.1007/s40265-013-0013-7 · DOI · Paper page
  15. Watkins, 2013, Novel beta-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance, Front. Microbiol., 4
  16. Castanheira, 2016, Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae, Antimicrob. Agents Chemother., 60, 5454, 10.1128/AAC.00711-16 · DOI
  17. Lapuebla, 2015, Activity of imipenem with relebactam against gram-negative pathogens from New York City, Antimicrob. Agents Chemother., 59, 5029, 10.1128/AAC.00830-15 · DOI · Paper page
  18. Biedenbach, 2015, In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013, Antimicrob. Agents Chemother., 59, 4239, 10.1128/AAC.00206-15 · DOI
  19. Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases, Antimicrob. Agents Chemother., 60, 4384, 10.1128/AAC.03098-15 · DOI · Paper page
  20. Page, 2010, In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli, Antimicrob. Agents Chemother., 54, 2291, 10.1128/AAC.01525-09 · DOI · Paper page
  21. Amunts, 2015, The structure of the human mitochondrial ribosome, Science, 348, 95, 10.1126/science.aaa1193 · DOI · Paper page
  22. Garcia-Salguero, 2015, Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?, Antimicrob. Agents Chemother., 59, 5959, 10.1128/AAC.00873-15 · doi:10.1128/aac.00873-15
  23. Davidovich, 2007, Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity, Proc. Natl. Acad. Sci. U.S.A., 104, 4291, 10.1073/pnas.0700041104 · DOI · Paper page
  24. Sader, 2012, Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections, Antimicrob. Agents Chemother., 56, 1619, 10.1128/AAC.05789-11 · doi:10.1128/aac.05789-11
  25. Prince, 2013, Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections, Antimicrob. Agents Chemother., 57, 2087, 10.1128/AAC.02106-12 · doi:10.1128/aac.02106-12
  26. Macone, 2014, In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline, Antimicrob. Agents Chemother., 58, 1127, 10.1128/AAC.01242-13 · DOI · Paper page
  27. Zhanel, 2016, Review of eravacycline, a novel fluorocycline antibacterial agent, Drugs, 76, 567, 10.1007/s40265-016-0545-8 · DOI · Paper page
  28. Fernandes, 2016, The solithromycin journey—it is all in the chemistry, Bioorg. Med. Chem., 10.1016/j.bmc.2016.08.035 · DOI
  29. Barrera, 2016, Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL), Lancet Infect. Dis., 16, 421, 10.1016/S1473-3099(16)00017-7 · doi:10.1016/s1473-3099(16)00017-7
  30. File, 2016, SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia, Clin. Infect. Dis., 63, 1007, 10.1093/cid/ciw490 · doi:10.1093/cid/ciw490
  31. Hook, 2015, A Phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea, Clin. Infect. Dis., 61, 1043, 10.1093/cid/civ478 · doi:10.1093/cid/civ478
  32. Keelan, 2016, A new, potent, and placenta-permeable macrolide antibiotic, solithromycin, for the prevention and treatment of bacterial infections in pregnancy, Front. Immunol., 7
  33. Bisacchi, 2015, Origins of the quinolone class of antibacterials: An expanded “discovery story”, J. Med. Chem., 58, 4874, 10.1021/jm501881c · DOI · Paper page
  34. Nakada, 1994, Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor, Antimicrob. Agents Chemother., 38, 1966, 10.1128/AAC.38.9.1966 · DOI
  35. So, 2015, Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model, Antimicrob. Agents Chemother., 59, 4956, 10.1128/AAC.00625-15 · DOI
  36. Foerster, 2015, Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae, Front. Microbiol., 6
  37. De Ambrogi, 2016, Highlights from the 26th ECCMID, Lancet Infect. Dis., 16, 645, 10.1016/S1473-3099(16)30094-9 · doi:10.1016/s1473-3099(16)30094-9
  38. Gerding, 2016, Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection, J. Antimicrob. Chemother., 71, 213, 10.1093/jac/dkv300 · DOI
  39. Chuanchuen, 2001, Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ, Antimicrob. Agents Chemother., 45, 428, 10.1128/AAC.45.2.428-432.2001 · DOI · Paper page
  40. Karlowsky, 2009, AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity, Antimicrob. Agents Chemother., 53, 3544, 10.1128/AAC.00400-09 · DOI
  41. Yum, 2007, In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea, Antimicrob. Agents Chemother., 51, 2591, 10.1128/AAC.01562-06 · doi:10.1128/aac.01562-06
  42. Sader, 2009, Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates, Antimicrob. Agents Chemother., 53, 2171, 10.1128/AAC.00129-09 · DOI
  43. Mensa, 2014, Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16, Antimicrob. Agents Chemother., 58, 5136, 10.1128/AAC.02955-14 · DOI · Paper page
  44. Vickers, 2016, Ridinilazole: a novel therapy for Clostridium difficile infection, Int. J. Antimicrob. Agents, 48, 137, 10.1016/j.ijantimicag.2016.04.026 · DOI
  45. Falagas, 2008, Fosfomycin: use beyond urinary tract and gastrointestinal infections, Clin. Infect. Dis., 46, 1069, 10.1086/527442 · doi:10.1086/527442
  46. Obrecht, 2009, Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics, Curr. Med. Chem., 16, 42, 10.2174/092986709787002844 · DOI
  47. Kali, 2015, Teixobactin: a novel antibiotic in treatment of gram-positive bacterial infections, J. Clin. Diagn. Res., 9, DL01
  48. Davidson, 2002, Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia, N. Eng. J. Med., 346, 747, 10.1056/NEJMoa012122 · DOI · Paper page
  49. Rex, 2016, Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach, Lancet Infect. Dis., 16, 500, 10.1016/S1473-3099(15)00500-9 · DOI
  50. Balasegaram, 2015, A pathway towards an alternative business model for antibiotic innovation: a framework, fund and institutional mechanism, J Law Med. Ethics (Special Supplement), 43, 22, 10.1111/jlme.12270 · DOI
  51. Brogan, 2013, Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model, Global. Health, 9, 58, 10.1186/1744-8603-9-58 · DOI

Cited by

See all 247

Metadata

Authors
Fernandes, P., & Martens, E.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2017-06
Volume
133
Pages
152-163
ISSN
0006-2952 (ISSN-L)
OpenAlex
W2524062943
Cited by
247
References
2
FWCI
12.76
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibiotics in late clinical development. https://app.cochat.ai/papers/10.1016/j.bcp.2016.09.025
The paper
Fernandes, P., & Martens, E. (2017). Antibiotics in late clinical development. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2016.09.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.